Matthew Adam Gline, an officer and director of Roivant Sciences Ltd., filed a Form 144 notice on November 10, 2026, proposing the sale of 164,136 shares of common stock acquired through Performance Stock Units.
Key Highlights
- Filer and role: Matthew Adam Gline is listed as both an officer and a director of Roivant Sciences Ltd.
- Shares proposed for sale: 164,136 shares of common stock, with an aggregate market value of $6,729,576.00, according to the filing.
- Source of shares: The securities were acquired on November 10, 2026, through Performance Stock Units issued by the issuer, with the nature of payment listed as "Services Rendered."
- Total shares outstanding: The filing reports 724,561,460 shares of common stock outstanding.
- Broker designated: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.
- Prior sales: The filing reports nothing to disclose under securities sold during the past 3 months.
- Exchange: The securities are listed on NASDAQ, as stated in the filing.
Roivant Sciences Officer Gline Proposes Rule 144 Sale of PSU-Derived Shares
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Matthew Adam Gline, identified as both an officer and a director of Roivant Sciences Ltd. (NASDAQ:ROIV), is proposing to sell 164,136 shares of the company's common stock. The filing states an approximate sale date of November 10, 2026, the same date the notice was submitted and the date the shares were acquired.
The filing discloses that the shares to be sold were acquired through Performance Stock Units granted by Roivant Sciences Ltd. itself, with the nature of payment described as "Services Rendered." No cash purchase was involved in the acquisition. The aggregate market value of the proposed sale is listed as $6,729,576.00. The filing also indicates that total shares of common stock outstanding at the time of filing numbered 724,561,460.
Under the "Securities Sold During The Past 3 Months" section, the filing reports nothing to disclose, indicating no prior Rule 144 sales by Gline in that period. The Form 144 was signed by Matthew Adam Gline, and the notice includes the standard representation that the filer does not know of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.
What Was Disclosed
Roivant Sciences officer and director Matthew Adam Gline filed a Form 144 notice on November 10, 2026, proposing to sell 164,136 common shares, valued at $6,729,576.00, acquired that same day through Performance Stock Units for services rendered.



Please wait processing your request...